H101溶瘤病毒治疗联合替利单抗治疗晚期肝癌的体外效应：1例报告

IF 2.9 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2025-06-15 eCollection Date: 2025-01-01 DOI:10.62347/VSQY6496

Danzhen Ou, Yijing Li, Jingjing Wu, Shunjie Ou, Fangwei Xie

{"title":"H101溶瘤病毒治疗联合替利单抗治疗晚期肝癌的体外效应：1例报告","authors":"Danzhen Ou, Yijing Li, Jingjing Wu, Shunjie Ou, Fangwei Xie","doi":"10.62347/VSQY6496","DOIUrl":null,"url":null,"abstract":"We reported a case of advanced hepatocellular carcinoma (HCC) in a patient who relapsed after first-line chemoimmunotherapy. Remarkably, the combination of H101 oncolytic virotherapy and tislelizumab successfully induced an abscopal effect. Following this treatment, the patient achieved a 24-month survival period, accompanied by complete regression of distant metastatic lesions. Distinct tumor responses were observed at different sites following H101 injection. Lesions showing regression demonstrated higher infiltration of CD3+ T cells, CD4+ T cells, and eosinophils, along with lower infiltration of neutrophils. Rapid tumor shrinkage was associated with severe local inflammation and a reduction in peripheral white blood cell counts. These findings suggest that oncolytic virotherapy may elicit an abscopal effect by activating and recruiting immune cells into the tumor microenvironment.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2650-2656"},"PeriodicalIF":2.9000,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256427/pdf/","citationCount":"0","resultStr":"{\"title\":\"Induction of abscopal effect combining H101 oncolytic virotherapy with tislelizumab in a patient with advanced hepatocellular carcinoma: a case report.\",\"authors\":\"Danzhen Ou, Yijing Li, Jingjing Wu, Shunjie Ou, Fangwei Xie\",\"doi\":\"10.62347/VSQY6496\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We reported a case of advanced hepatocellular carcinoma (HCC) in a patient who relapsed after first-line chemoimmunotherapy. Remarkably, the combination of H101 oncolytic virotherapy and tislelizumab successfully induced an abscopal effect. Following this treatment, the patient achieved a 24-month survival period, accompanied by complete regression of distant metastatic lesions. Distinct tumor responses were observed at different sites following H101 injection. Lesions showing regression demonstrated higher infiltration of CD3+ T cells, CD4+ T cells, and eosinophils, along with lower infiltration of neutrophils. Rapid tumor shrinkage was associated with severe local inflammation and a reduction in peripheral white blood cell counts. These findings suggest that oncolytic virotherapy may elicit an abscopal effect by activating and recruiting immune cells into the tumor microenvironment.\",\"PeriodicalId\":7437,\"journal\":{\"name\":\"American journal of cancer research\",\"volume\":\"15 6\",\"pages\":\"2650-2656\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256427/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.62347/VSQY6496\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/VSQY6496","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们报告了一例晚期肝细胞癌（HCC）患者在一线化疗免疫治疗后复发。值得注意的是，H101溶瘤病毒疗法和tislelizumab的联合成功地诱导了体外效应。经过这种治疗，患者获得了24个月的生存期，并伴有远处转移性病变的完全消退。注射H101后，不同部位观察到不同的肿瘤反应。病变消退表现为CD3+ T细胞、CD4+ T细胞和嗜酸性粒细胞的高浸润，中性粒细胞的低浸润。肿瘤迅速缩小与严重的局部炎症和外周血白细胞计数减少有关。这些发现表明，溶瘤病毒疗法可能通过激活和招募免疫细胞进入肿瘤微环境而引起体外效应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Induction of abscopal effect combining H101 oncolytic virotherapy with tislelizumab in a patient with advanced hepatocellular carcinoma: a case report.

We reported a case of advanced hepatocellular carcinoma (HCC) in a patient who relapsed after first-line chemoimmunotherapy. Remarkably, the combination of H101 oncolytic virotherapy and tislelizumab successfully induced an abscopal effect. Following this treatment, the patient achieved a 24-month survival period, accompanied by complete regression of distant metastatic lesions. Distinct tumor responses were observed at different sites following H101 injection. Lesions showing regression demonstrated higher infiltration of CD3⁺ T cells, CD4⁺ T cells, and eosinophils, along with lower infiltration of neutrophils. Rapid tumor shrinkage was associated with severe local inflammation and a reduction in peripheral white blood cell counts. These findings suggest that oncolytic virotherapy may elicit an abscopal effect by activating and recruiting immune cells into the tumor microenvironment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.